Log In
Print
BCIQ
Print
Print this Print this
 

Synagis, palivizumab (MEDI-493)

  Manage Alerts
Collapse Summary General Information
Company AstraZeneca plc
DescriptionHumanized mAb against respiratory syncytial virus (RSV)
Molecular Target RSV F protein
Mechanism of ActionBinds RSV F protein
Latest Stage of DevelopmentMarketed
IndicationRespiratory syncytial virus (RSV)
Partner

AbbVie Inc.
 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today